Show simple item record

dc.contributor.advisorWarholak, Terrien
dc.contributor.advisorRupp, Michael T.en
dc.contributor.authorSkulkan, Kaitlyn
dc.contributor.authorWarholak, Terri
dc.contributor.authorRupp, Michael T.
dc.date.accessioned2016-06-21T22:00:44Z
dc.date.available2016-06-21T22:00:44Z
dc.date.issued2016
dc.identifier.urihttp://hdl.handle.net/10150/614017
dc.descriptionClass of 2016 Abstracten
dc.description.abstractObjectives: To identify stakeholder concerns regarding a potential requirement that all prescriptions include the reason for use or indication. Methods: This was a mixed methods study that employed focus groups. Participants were invited by the Chief Executive Officer (CEO) of the Arizona Pharmacy Association (AzPA) to attend focus groups via webinar. E-mail invites were sent to AzPA members and members of Arizona healthcare professional associations with prescriptive authority except for prescribers who care for animals. The discussion began with a PowerPoint presentation and then questions were presented to guide discussion. Afterwards, questionnaires were distributed through e-mail. Interval level data were analyzed using means and standard deviations. The commentary of the focus group discussion was summarized in themes. Results: Preliminary findings, from two focus groups with a total of seven participants, reflected the following concerns with the inclusion of the indication on prescriptions: compromise of patient privacy; technology capabilities; prescriber time; prescriber compliance; and prior authorization complications. The proposed benefits were: enhanced communication; better medication counseling; reduced prescribing errors; decreased controlled substance diversion; and increased accuracy of a prospective drug use review by pharmacists for patients with complicated disease states. Conclusions: In conclusion, stakeholders were concerned with the implementation of including the indication on prescription orders.
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectArizonaen
dc.subjectArizona Pharmacy Association (AzPA)en
dc.subjectFocus Groupsen
dc.subjectIndicationen
dc.subjectPrescriptionen
dc.subject.meshPrescriptions
dc.titleIdentifying Concerns in Arizona with the Inclusion of the Indication or Reason for Use on the Prescription through Focus Groupsen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
html.description.abstractObjectives: To identify stakeholder concerns regarding a potential requirement that all prescriptions include the reason for use or indication. Methods: This was a mixed methods study that employed focus groups. Participants were invited by the Chief Executive Officer (CEO) of the Arizona Pharmacy Association (AzPA) to attend focus groups via webinar. E-mail invites were sent to AzPA members and members of Arizona healthcare professional associations with prescriptive authority except for prescribers who care for animals. The discussion began with a PowerPoint presentation and then questions were presented to guide discussion. Afterwards, questionnaires were distributed through e-mail. Interval level data were analyzed using means and standard deviations. The commentary of the focus group discussion was summarized in themes. Results: Preliminary findings, from two focus groups with a total of seven participants, reflected the following concerns with the inclusion of the indication on prescriptions: compromise of patient privacy; technology capabilities; prescriber time; prescriber compliance; and prior authorization complications. The proposed benefits were: enhanced communication; better medication counseling; reduced prescribing errors; decreased controlled substance diversion; and increased accuracy of a prospective drug use review by pharmacists for patients with complicated disease states. Conclusions: In conclusion, stakeholders were concerned with the implementation of including the indication on prescription orders.


This item appears in the following Collection(s)

Show simple item record